In:
Diabetes, American Diabetes Association, Vol. 68, No. Supplement_1 ( 2019-06-01)
Abstract:
Introduction: We assessed the efficacy of three glucose-lowering interventions in persons with HbA1c-defined prediabetes. Methods: 120 participants were randomised 1:1:1:1 to 13 weeks of 1) dapagliflozin (DAP, 10 m/day); 2) metformin (MET, 1700 mg/day); 3) exercise (EXE, 5 x 30 min/week); or 4) control (CON, no treatment). Continuous glucose monitor (CGM) was used for 6 days before, during (6 weeks) and after (13 weeks) the intervention. Treatments were stopped the day before the last visit (two days before in EXE). Primary outcome was 13-week change in mean amplitude of glycaemic excursions (MAGE). Intention-to-treat analysis was conducted. Results: At baseline, median (Q1;Q3) HbA1c was 5.9 (5.7;6.1)%; BMI 30.8 (28.6;34.3) kg/m2; age 62 (54;68) years; 44% were men. No within- or between-group changes were observed for MAGE. Mean CGM glucose (MG) was slightly reduced in MET and DAP at 6 weeks (Table 1). The 6-week change in MG in DAP was different from that in CON (mean diff. (95% CI): -0.3 mM (-0.5;0.0), P=0.031). At 13 weeks, MG had increased in MET and CON, and the change in MET was different from those in EXE (0.2 mM (0.0;0.5), P=0.041) and DAP (0.2 mM (0.0;0.5), P=0.039). Conclusion: 13 weeks of treatment with MET, DAP or EXE did not change MAGE. Treatment with DAP or MET for 6 weeks slightly reduced MG; these improvements disappeared immediately after treatments were stopped at 13 weeks. Disclosure K. Færch: Research Support; Self; Ascensia Diabetes Care, AstraZeneca, Unilever. Stock/Shareholder; Self; Novo Nordisk A/S. D. Vistisen: Stock/Shareholder; Self; Novo Nordisk A/S. M.B. Blond: None. L.B. Nielsen: None. H. Amadid: None. T.F. Dejgaard: Consultant; Self; Novo Nordisk A/S. Research Support; Self; AstraZeneca, Novo Nordisk A/S. Speaker's Bureau; Self; Boehringer Ingelheim International GmbH. M. Ried-Larsen: Other Relationship; Self; Novo Nordisk A/S. K. Karstoft: Employee; Self; Novo Nordisk A/S. F. Persson: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk A/S. Research Support; Self; AstraZeneca, Sanofi. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi. M.E. Jørgensen: Research Support; Self; Amgen Inc., AstraZeneca, Danish Diabetes Association, Sanofi-Aventis. Stock/Shareholder; Self; Novo Nordisk A/S. Funding Novo Nordisk Foundation; AstraZeneca
Type of Medium:
Online Resource
ISSN:
0012-1797
,
1939-327X
Language:
English
Publisher:
American Diabetes Association
Publication Date:
2019
detail.hit.zdb_id:
1501252-9
Permalink
